A series of studies reveals how a single gut microbe can protect against infections and influence pregnancy outcomes, but warns that the effects can vary widely depending on diet, disease, and host biology.
Research: Microbes on the move: Akkermansia in infectious diseases and their emerging role in gynecological health. Image credit: FOTOGRIN/Shutterstock.com
In a recent mini-review published in bacteriology journala group of authors summarized existing evidence on the role of . Akkermansia muciniphila About infectious diseases and their emerging impact on gynecological health.
Gut bacteria are involved in metabolism, immunity, and pregnancy outcome
Akkermansia muciniphila is a common mucin-degrading bacterium found in the gastrointestinal (GI) tract, making up 1–3% of the intestinal flora. It has been noted for its health benefits, including improving metabolism, strengthening the intestinal barrier, and reducing inflammation.
Emerging preclinical and observational evidence suggests that: Akkermansia muciniphila It also affects how well you handle various infections and gynecological health, including pregnancy-related conditions. Its effects are complex and context-dependent, and further research is needed to clarify its therapeutic potential.
overview Akkermansia muciniphila
Akkermansia muciniphila It is a Gram-negative, anaerobic bacterium that colonizes the gastrointestinal tract and uses mucin as its main nutritional source. This bacterium has attracted attention since its discovery in 2004. It has been shown to modulate host metabolism and immune responses. It also plays a role in maintaining the intestinal barrier, preventing harmful substances from entering the bloodstream, and ensuring balance within the gut microbiome.
This association of bacterial function has become very important in today’s society, where unhealthy food, stress, and excessive antibiotic use often create imbalances in the gastrointestinal tract.
Role in gastrointestinal infections
role of Akkermansia muciniphila Gastrointestinal infections show both protective and context-dependent effects. Infectious diseases caused by pathogens such as clostridium difficile, Typhimuriumenterotoxigenic Escherichia coli (ETEC), supplementary Akkermansia muciniphila It is associated with reduced inflammation, improved intestinal barrier function, and, in some models, reduced disease severity and pathogen burden.
However, other experimental models have shown that it worsens infections by disrupting the mucus layer and increasing pathogen entry. different ways Akkermansia muciniphila The interaction with organisms highlights how factors such as diet, microbiota composition, and host immune status can play important roles in the outcome of supplements with respect to gastrointestinal infections.
Role in systemic and viral infections
Beyond the intestines Akkermansia muciniphila Affects systemic infections such as sepsis, viral infections, and parasitic diseases. Specifically, septic patients have lower levels of Akkermansia species, which is associated with poor prognosis. Increased Akkermansia abundance and enriched fecal microbiota transfer from donors are associated with improved survival in animal models, and administration of live bacteria or derived molecules (such as peptides) has shown protective effects through anti-inflammatory mediators in preclinical studies.
Higher levels are associated with different immune response profiles, suggesting that Akkermansia plays a role in disease severity. Additionally, several studies on individuals infected with parasites (malaria and helminths) have shown that Akkermansia levels correlate with disease progression, suggesting a potential role as a biomarker for these diseases.
Role in respiratory and oral infections
Emerging evidence suggests a link between gut microbiota and respiratory health through the gut-lung axis. Akkermansia muciniphila Protects against lung infections such as influenza A (H7N9) and tuberculosis (TB). It also improves immune responses, reduces inflammation, and increases survival in infected animal models.
In periodontitis (inflammation of the periodontal tissue), this bacteria has been shown to reduce inflammation and tissue damage. These findings highlight its potential role in the management of chronic inflammatory conditions beyond the gut and demonstrate its relevance to everyday health problems such as periodontal disease.
A new role in gynecological health
One of the most exciting developments is Akkermansia muciniphila For gynecological and pregnancy-related conditions. Low levels of Akkermansia are seen in pre-eclampsia (PE), an important complication during pregnancy associated with hypertension. In animal studies, the supplement improved placental health and reduced fetal inflammation.
Women with gestational diabetes mellitus (GDM) have lower levels of Akkermansia in their gut microbiota, and treatment may improve insulin sensitivity and reduce inflammatory markers. Akkermansia has also been linked to women’s health and the female reproductive system and may be involved in bacterial vaginosis (BV), preterm birth (PTB), and human papillomavirus (HPV) infections. However, these relationships are primarily observational and correlational, and there is limited evidence for direct interventions outside of the PE and GDM models.
Mechanisms of action and context-dependent effects
beneficial effects Akkermansia muciniphila They are primarily driven by their ability to strengthen the intestinal barrier, modulate immune responses, and produce bioactive molecules. These include proteins such as Amuc_1100, extracellular vesicles (EVs), and metabolites that modulate inflammation and host signaling pathways.
However, this is not always beneficial. Many factors can change its usefulness Akkermansia muciniphila. For example, low fiber conditions can lead to excessive mucin breakdown, weakening the intestinal barrier and increasing susceptibility to infections. This dual nature highlights the importance of individualized approaches in microbiome-based therapy.
Clinical and therapeutic potential
Considering its wide range of effects, Akkermansia muciniphila It is being researched as a next-generation probiotic. Benefits have been shown for both live and pasteurized bacteria, with pasteurized bacteria often showing equal or greater efficacy.
From a real-world perspective, this research could also enable the development of probiotics that promote successful pregnancy and improve immune responses to infections. These microbiome-based health interventions have the potential to inform future strategies to combat ineffective antibiotic treatments and the alarming rise in chronic diseases around the world, particularly where antibiotic resistance has become one of the most pressing global public health concerns.
Akkermansia affects immunity, infection, and pregnancy-related outcomes
This review highlights: Akkermansia muciniphila It plays a critical role in regulating host immunity, maintaining intestinal integrity, and influencing disease outcome across infectious and gynecological diseases.
Based on experimental and observational studies, Akkermansia muciniphila It is considered to have promising but early stage therapeutic potential (especially as a probiotic). Given that most of the studies have used animal models, more clinical studies are needed to provide additional evidence for clinical practice.
Furthermore, researchers need a deeper understanding of the mechanisms so that their discoveries can be translated into actionable and personalized medical solutions. Importantly, many studies have identified Akkermansia at the genus level and identified species-specific effects, including: A. muciniphila) may vary due to resolution limitations.
Click here to download your PDF copy.
Reference magazines:
-
Marroquin, S. M., Dolan, K. S. (2026). Microbes on the move: Akkermansia in infectious diseases and their emerging role in gynecological health. Journal of Bacteriology. Toi: 10.1128/jb.00491-25. https://journals.asm.org/doi/10.1128/jb.00491-25
